Illuminating the many faces of pulmonary hypertension

Affiliations

¹ Royal Papworth Hospital, Cambridge CB2 0AY, UK; Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
² Royal Papworth Hospital, Cambridge CB2 0AY, UK; Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK. Electronic address: joanna.pepke-zaba@nhs.net.

Comment

Joseph Newman et al. Lancet Respir Med. 2023 Sep.

. 2023 Sep;11(9):760-762.

doi: 10.1016/S2213-2600(23)00291-6. Epub 2023 Aug 14.

¹ Royal Papworth Hospital, Cambridge CB2 0AY, UK; Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK.
² Royal Papworth Hospital, Cambridge CB2 0AY, UK; Victor Phillip Dahdaleh Heart and Lung Research Institute, Department of Medicine, School of Clinical Medicine, University of Cambridge, Cambridge, UK. Electronic address: joanna.pepke-zaba@nhs.net.

No abstract available

Conflict of interest statement

JP-Z serves on advisory boards for Janssen, MSD, Gossamer, and United Therapeutics. JN declares no competing interests.

Treatment of pulmonary arterial hypertension: recent progress and a look to the future.
Humbert M, Sitbon O, Guignabert C, Savale L, Boucly A, Gallant-Dewavrin M, McLaughlin V, Hoeper MM, Weatherald J. Humbert M, et al. Lancet Respir Med. 2023 Sep;11(9):804-819. doi: 10.1016/S2213-2600(23)00264-3. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591298 Review.
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.
Delcroix M, de Perrot M, Jaïs X, Jenkins DP, Lang IM, Matsubara H, Meijboom LJ, Quarck R, Simonneau G, Wiedenroth CB, Kim NH. Delcroix M, et al. Lancet Respir Med. 2023 Sep;11(9):836-850. doi: 10.1016/S2213-2600(23)00292-8. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591299 Review.